Connect with us

Business

Georgiu appointed CEO of NZ Breakers

Published

on

Georgiu appointed CEO of NZ Breakers

Former Perth Wildcats chief executive Troy Georgiu has been appointed chief executive of the New Zealand Breakers, effective immediately.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Business

Barclays Has ‘Levers’ to Pull if Trump Administration Caps Credit-Card Rates

Published

on

Barclays Has 'Levers' to Pull if Trump Administration Caps Credit-Card Rates

Barclays, a big player in U.S. credit cards, reckons it has ways to protect that business if the Trump administration pushes through a 10% cap on interest rates.

After the president called for the ceiling last month, shares of Barclays and U.S. card rivals fell. JPMorgan Chase CEO Jamie Dimon said the policy risked “economic disaster.”

Reporting earnings Tuesday, Barclays sounded more sanguine. Chief Financial Officer Anna Cross said the bank can pull a “number of levers,” but there are so many possible outcomes she couldn’t give any financial guidance about the policy.

Continue Reading

Business

Stocks to Watch Tuesday: Coca-Cola, Onsemi, Spotify

Published

on

Coca-Cola posted quarterly earnings this morning.

↗️ Spotify (SPOT): The audio streamer’s quarterly results topped forecasts, fueling a premarket rally in its shares.

Continue Reading

Business

Data centre and renewable investment plans at Global Centre of Rail Excellence site delayed

Published

on

Business Live

The project is seeking to sell land for major data centre and energy investment to plug a funding gap for the rail testing project

How the Global Centre of Rail Excellence could look.

Plans to secure a major data centre and renewable energy investment to help fund the £400m Global Centre of Rail Excellence (GCRE) project have been pushed back. The overall project, proposed by the Welsh Government seven years ago, is earmarked for a 700-hectare site – the size of Gibraltar – at Onllwyn in the Dulais Valley.

The Welsh Government wholly-owned company behind the project, GCRE Ltd, has been in the marketplace seeking to raise £330m in private funding for the scheme, which would be the world’s first integrated testing facility for both trains and rail infrastructure equipment. The project has already secured, and is close to spending, £50m from the Welsh Government and £20m from the former Conservative UK Government to prepare the site, including the construction of an electricity substation.

Advertisement

The testing facility would consist of two electrified seven kilometre looped testing tracks for rolling stock and infrastructure, both designed to operate 24/7 year-round. It would also include train storage and maintenance facilities, a control centre, a 100-bedroom hotel, as well as training and research and development functions.

READ MORE: Who are Y11 Sport and Media who are in line to acquire Cardiff RugbyREAD MORE: The £30m elevated walkway project that would link Penarth and Cardiff Bay

A later phase, outside of the £400m fundraising package, could also see the development of a rail-related technology park, potentially funded privately.

Fundraising efforts initially focused on securing equity and progressed to talks with three potential investors, including one Middle Eastern investor. When a deal failed to materialise, GCRE entered into advanced negotiations with a long-term debt funder. While confident of closing a deal, the proposed investor – which was also seeking a guarantee from the Welsh Government on its lending – opted at a late stage not to proceed. Whether the project is funded by debt, equity, or a combination of the two.

Advertisement

Ultimately the market determines what amount it is prepared investment. While there is interest, and GCRE Ltd are confident of the testing facility becoming profitable in its early years, there is not the risk appetite to commit £330m, so at present further government funding will be required.

To help narrow the funding gap, GCRE last year sought an energy and data centre partner (EDCP) through an invitation-to-tender process, with the aim of securing a preferred developer before the Senedd election in May. However, the initial timeframe for expressions of interest was deemed too short by interested parties to develop comprehensive proposals for the site. As a result, a new invitation to tender, through Sell2Wales, has been launched with a deadline of March 10.

GCRE site.

GCRE Ltd envisages it will be in a position to take forward three shortlisted bidders in the summer. Following detailed dialogue, a preferred investor – assuming a deal can be struck – is expected to be confirmed by the end of the year. Any land deal, which is most likely to be with a developer that would then strike agreements to bring in data centre and renewable energy operators, is expected to generate tens of millions of pounds towards the rail testing facility.

The current Labour administration remains supportive of the project and has indicated a willingness to provide additional funding to close any gap. However, it would be for the next Cardiff Bay administration to decide whether to take the project forward.

Advertisement

If the required funding is secured, the company status of GCRE Ltd may also need to be changed to ensure it is not viewed by the UK Treasury as being part of the Welsh Government accounting framework.

Otherwise, private investment could be treated as part of the Welsh Government’s block grant, meaning an equivalent amount would need to be held in reserve. While this is ultimately a matter of classification for the Office for National Statistics, one potential solution would be for GCRE to become a community interest company.

Simon Jones CEO of GCRE Ltd.(Image: John Myers)

Chief executive of GCRE Ltd, Simon Jones, said: “The last few weeks have been very encouraging, as we have seen the significant interest there is from the commercial market in the GCRE site as a location for high-quality renewable energy and data centre infrastructure.

“What’s clear, however, is that more time is needed for bidders to develop their proposals. That has meant we have taken the decision as a company to extend our partner search and give everyone in the market more time to put forward proposals.

Advertisement

“That is why we have issued a new invitation to tender with an extended timeline, allowing that interest to crystallise into firm proposals. We had originally hoped to appoint a partner by the end of the current Senedd term, but that has not been possible, and so we have extended the time available into 2026.

“The opportunity for a long-term partnership with GCRE is a unique one. The site’s size, power grid and telecoms connectivity make it very appealing for the development of renewable energy assets and data centre infrastructure. Both 132kV and 400kV power lines cross the GCRE site, with high-quality fibre connectivity being progressed for the area.

“It’s right that we take the time to find the correct partner. Energy and data centre infrastructure at GCRE will help raise the economic profile of the site, which is very important as we continue our search for private investment for the rail project.”

The rail centre has received expressions of interest from more than 200 firms looking to utilise its facilities, including Network Rail, Transport for Wales, and leading train manufacturers such as Hitachi and its Spanish rival Construcciones y Auxiliar de Ferrocarriles (CAF), which has a train manufacturing plant in Newport.

Advertisement

An economic assessment by professional services firm PwC suggests that over ten years – excluding the planned later phase, the Sarn Helen Technology Park – GCRE could create 1,100 permanent jobs, with a £300m gross value added (GVA) impact on the local area and £1.2bn over its lifetime. The project has also been forecast to generate a 15-fold economic return for every £1 invested.

Continue Reading

Business

Wegovy maker Novo Nordisk sues rival over ‘knock-off’ weight-loss drugs

Published

on

Wegovy maker Novo Nordisk sues rival over 'knock-off' weight-loss drugs

Novo Nordisk referenced the FDA’s concerns in its lawsuit announcement on Monday, saying Hims & Hers’ compounded drugs “may contain dangerous impurities or incorrect amounts of active ingredients, which can result in life-threatening immune responses”.

Continue Reading

Business

Entegris shares rise 7% after beating Q4 expectations

Published

on


Entegris shares rise 7% after beating Q4 expectations

Continue Reading

Business

UK gilt yields could spike if Starmer faces left-wing challenge, Jefferies warns

Published

on


UK gilt yields could spike if Starmer faces left-wing challenge, Jefferies warns

Continue Reading

Business

UK secures 6.2GW of onshore wind and solar in latest clean power auction

Published

on

UK secures 6.2GW of onshore wind and solar in latest clean power auction

The UK Government has confirmed a new wave of onshore renewable energy projects under the Contracts for Difference scheme, following last month’s record-breaking offshore wind auction.

Results from Allocation Round 7 (AR7) show 4.9GW of solar and 1.3GW of onshore wind capacity secured across Britain, reinforcing the pace at which clean power is being rolled out across the country.

Solar projects were awarded contracts at a strike price of £65.23 per megawatt hour (in 2024 prices), below the £70/MWh achieved in Allocation Round 6 and representing the largest volume of solar capacity ever secured in a single CfD auction.

Onshore wind projects were secured at a strike price of £72/MWh, slightly above the AR6 average of £71/MWh but still below the £73/MWh seen in Allocation Round 5, reflecting continued cost stability in the sector.

Once built, the projects announced today will lift the UK’s total CfD-supported wind and solar capacity to 50.6GW, including schemes already operational or under construction. The UK currently has 16.3GW of installed onshore wind capacity and more than 21GW of solar capacity, based on figures up to September 2025.

Advertisement

In total, AR7 has secured 14.7GW of renewable energy projects across all technologies, marking another significant step towards decarbonising the power system and strengthening domestic energy supply.

Frankie Mayo, senior analyst at Ember, said the results underlined the momentum behind clean power deployment across Britain.

“This is a great clean power achievement,” Mayo said. “Wind and solar are unstoppable across Britain, with new projects announced today unlocking access to reliable, homegrown energy and cutting our reliance on volatile fossil fuels for decades to come.”

The latest CfD results come as ministers continue to position renewable energy as central to the UK’s long-term energy security and net zero strategy, with onshore wind and solar increasingly seen as among the fastest and most cost-effective technologies to deploy at scale.

Advertisement

Jamie Young

Jamie Young

Jamie is Senior Reporter at Business Matters, bringing over a decade of experience in UK SME business reporting.
Jamie holds a degree in Business Administration and regularly participates in industry conferences and workshops.

When not reporting on the latest business developments, Jamie is passionate about mentoring up-and-coming journalists and entrepreneurs to inspire the next generation of business leaders.

Advertisement
Continue Reading

Business

Forrests’ Minderoo weirs stoush nears end

Published

on

Forrests’ Minderoo weirs stoush nears end

A legal dispute between the Forrests and the Thalanyji people over leaky weirs on Minderoo Station is nearing the end, as lawyers make their final submissions.

Continue Reading

Business

CVS Health (CVS) earnings Q4 2025

Published

on

CVS Health (CVS) earnings Q4 2025

A pedestrian walks by a CVS store in Greenbrae, California, on July 31, 2025.

Justin Sullivan | Getty Images

CVS Health on Tuesday reported fourth-quarter earnings and revenue that beat estimates and reaffirmed the 2026 profit guidance that impressed investors, signaling steady progress in the health-care giant’s turnaround plan. 

Advertisement

“’24 was a tough year for the company. So ’25 righted the ship,” CVS CFO Brian Newman said in an interview.

CVS, which operates one of the largest pharmacy chains in the U.S., sees full-year profit coming in between $7 to $7.20 per share. That’s in line with the $7.17 per share that analysts were expecting, according to LSEG. 

Newman also said the company is maintaining its 2026 revenue guidance of at least $400 billion. Analysts expect revenue of $409.77 billion, according to LSEG, though it’s unclear if those estimates account for all of the headwinds Newman cited.

He said that guidance includes $20 billion in headwinds, roughly half of which is driven by the company’s move to exit the Affordable Care Act individual exchange market this year. Newman said the other half reflects the company’s retail business adjusting to lower drug prices after the “most favored nation” deals that President Donald Trump struck with more than a dozen pharma companies in recent months.

Advertisement

CVS last week said its roughly 9,000 pharmacies are accepting discount cards from the president’s newly launched direct-to-consumer platform, TrumpRx, for eligible patients. Newman said CVS shares the Trump administration’s goal of reducing costs. He added that the lower prices set a new starting point from which Caremark, the company’s pharmacy benefit manager, can negotiate even lower costs for its clients, “so we don’t see these as kind of adversarial relationships.”

CVS previously said it expects growth this year to be driven by the return to target margins at its recovering Aetna insurance business, led by privately run Medicare Advantage plans, and Caremark. 

Newman added that primary-care provider Oak Street Health is “improving its profitability” this year. That comes after CVS moved to close 16 underperforming Oak Street locations. For the retail pharmacy business, Newman said the company has several tailwinds, such as new technological investments and the locations and new customers CVS acquired from Rite Aid last year after it filed for bankruptcy.

Investors rewarded CVS last year as CEO David Joyner, who stepped into the role in late 2024, pressed ahead with a sweeping restructuring aimed at reversing years of underperformance. The company has cut costs, reshuffled leadership and exited weaker markets, helping fuel a roughly 40% stock rise over the past year.

Advertisement

Here’s what CVS reported for the fourth quarter compared with what Wall Street was expecting, based on a survey of analysts by LSEG: 

  • Earnings per share: $1.09 adjusted vs. 99 cents expected
  • Revenue: $105.69 billion vs. $103.59 billion expected

The company posted net income of $2.92 billion, or $2.30 per share, for the fourth quarter. That compares with net income of $1.62 billion, or $1.30 cents per share, for the same period a year ago. 

Excluding certain items, such as restructuring charges and capital losses, adjusted earnings were $1.09 per share for the quarter.

CVS booked sales of $105.69 billion for the fourth quarter, up 8.2% from the same period a year ago, as all three of its business segments showed growth. 

Growth across business units

The insurance business brought in $36.29 billion in revenue during the quarter, up more than 10% from the fourth quarter of 2024. 

Advertisement

Newman said the unit delivered a “very strong” quarter and that he expects another year of margin improvement, primarily driven by Medicare Advantage. The company’s business for those privately run Medicare plans is “continuing the path towards target margins” of 3% to 4% by 2028, he said.

Aetna and other insurers have grappled with higher-than-expected medical costs over the past year as more Medicare Advantage patients return to hospitals for procedures they delayed during the pandemic. While medical costs remain high, Aetna and other insurers, such as UnitedHealthcare, appear to be becoming better equipped to navigate the issue moving forward.

Still, Newman said “we will continue the elevated trends. … I don’t think it’s too early to assume anything other than a prudent outlook.”

The insurance segment’s medical benefit ratio — a measure of total medical expenses paid relative to premiums collected — remained consistent from the prior year, at 94.8%. A lower ratio typically indicates that a company collected more in premiums than it paid out in benefits, resulting in higher profitability.

Advertisement

Newman said the biggest driver of that ratio in the fourth quarter was Medicaid pass-through payments that hit in late December.

In a release, CVS also said improved performance in the unit’s government business was offset by shifts in Medicare drug cost timing following changes under the Inflation Reduction Act, which altered the usual seasonal pattern of prescription spending.

Last month, shares of Medicare Advantage insurers took a hit in January after the Trump administration proposed nearly flat government payment rates to those plans in 2027. Newman said he does not believe that the proposed rate reflects medical cost trends.

CVS has started a dialogue with the Centers for Medicare and Medicaid Services before the agency finalizes the rate notice in the beginning of April, he added.

Advertisement

CVS’ pharmacy and consumer wellness division posted $37.66 billion in sales for the fourth quarter, up 12.4% from the same period a year earlier.

CVS said the increase came partly from higher prescription volume, including from the company’s acquisition of prescriptions from Rite Aid, but was offset by pharmacy reimbursement pressure and the impact of some generic drugs entering the market. 

That unit dispenses prescriptions in CVS’ more than 9,000 retail pharmacies and provides other services, such as vaccinations and diagnostic testing.

CVS’ health services segment generated $51.24 billion in revenue for the quarter, up 9% compared with the same quarter in 2024. 

Advertisement

That unit includes Caremark, which negotiates drug discounts with manufacturers on behalf of insurance plans, creates lists of medications, or formularies, that are covered by insurance, and reimburses pharmacies for prescriptions.

Continue Reading

Business

Coca-Cola (KO) Q4 2025 earnings

Published

on

Coca-Cola (KO) Q4 2025 earnings

Cases of Coca-Cola brand soda are stacked at a Costco Wholesale store on November 13, 2025 in Simi Valley, California.

Kevin Carter | Getty Images

Coca-Cola is expected to report its fourth-quarter earnings before the bell on Tuesday.

Advertisement

Here’s what Wall Street analysts surveyed by LSEG are expecting the company to report:

  • Earnings per share: 56 cents expected
  • Revenue: $12.03 billion expected

Like rival PepsiCo, Coke has seen demand for its drinks soften in recent quarters as low-income shoppers look to save on their grocery bills. But the beverage giant’s pricier brands, like Fairlife and Smartwater, have been bright spots for the company, showing that high-income consumers are still willing to pay more for premium drinks.

This will mark CEO James Quincey’s last earnings report as chief executive. In December, the company announced that COO Henrique Braun will succeed him as CEO, effective March 31. Quincey will remain on Coke’s board as executive chair.

Shares of Coca-Cola have risen roughly 22% over the last year, raising its market value up to about $335 billion.

Advertisement
Continue Reading

Trending

Copyright © 2025